Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 4097195, 9 pages
Research Article

In Vitro and In Vivo Studies on Quercus acuta Thunb. (Fagaceae) Extract: Active Constituents, Serum Uric Acid Suppression, and Xanthine Oxidase Inhibitory Activity

1College of Pharmacy, Pusan National University, Geumjeong, Busan 46241, Republic of Korea
2Department of Oriental Medicine Materials, Dongshin University, Naju, Jeonnam 58245, Republic of Korea
3Department of Environmental Engineering, Mokpo National University, Muan, Jeonnam 58554, Republic of Korea
4Jeollanamdo Wando Arboretum, Wando, Jeonnam 59105, Republic of Korea
5Department of Pharmacy, College of Pharmacy, Mokpo National University, Muan, Jeonnam 58554, Republic of Korea
6Jeonnam Bioindustry Foundation, Institute of Natural Resources Research, Jangheung, Jeonnam 59338, Republic of Korea

Correspondence should be addressed to In-Soo Yoon; and Seung-Sik Cho;

Received 28 September 2016; Revised 29 November 2016; Accepted 1 December 2016; Published 22 March 2017

Academic Editor: Kuttulebbai N. S. Sirajudeen

Copyright © 2017 In-Soo Yoon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Quercus acuta Thunb. (Fagaceae) (QA) is cultivated as a dietary and ornamental plant in China, Japan, South Korea, and Taiwan. It has been widely used as the main ingredient of acorn tofu, a traditional food in China and South Korea. The aim of this study was to determine in vitro and in vivo xanthine oxidase (XO) inhibitory and antihyperuricemic activities of an ethyl acetate extract of QA leaf (QALE) and identify its active phytochemicals using gas chromatography-mass spectrometry (GC-MS) and liquid chromatography (LC) systems. The QALE was found to possess potent in vitro antioxidant and XO inhibitory activities. In vivo study using hyperuricemic mice induced with potassium oxonate demonstrated that the QALE could inhibit hepatic XO activity at a relatively low oral dose (50 mg/kg) and significantly alleviate hyperuricemia to a similar extent as allopurinol. Several active compounds including vitamin E known to possess XO inhibitory activity were identified from the QALE. To the best of our knowledge, this is the first study that reports the active constituents and antihyperuricemic effect of QA, suggesting that it is feasible to use QALE as a food therapy or alternative medicine for alleviating hyperuricemia and gout.